Table 2.

Pairwise comparison of KRAS mutations and overall survival in PDAC patients.

Parameter	CTC KRAS G12V	CTC KRAS other mutation	CTC cyto positive KRAS WT	CTC Negative
n = 58	14 (24.1%)	28 (48.3%)	11 (19%)	5 (8.6%)
CTC KRAS G12V		P = 0.21	P = 0.04	P = 0.26
CTC KRAS other mutation	P = 0.21		P = 0.23	P = 0.90
CTC positive KRAS WT	P = 0.04	P = 0.23		P = 0.67
CTC Negative	P = 0.26	P = 0.90	P = 0.67
Median OS, months	24.5	10	8	8
P	0.63
Alive at end of study period (2/2016)	3	8	2	1